Disclosed are a polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate of general formula (I) and a drug composition comprising the conjugate. In the conjugate, PEG represents polyethylene glycol of a molecular weight of 300-60,000 Daltons

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

The disclosure relates to compounds and compositions for bone formation fracture treatment bone grafting bone fusion cartilage maintenance and repair and methods related thereto. In certain embodiments the disclosure relates to compositions comprising one or more compound(s) disclosed herein such as clotrimazole honokiol magnolol tacrolimus pimecrolimus sirolimus everolimus temsirolimus spironolactone fluticasone fluticasone propionate fluticasone furoate linezolid telmisartan chlorambucil retin...

In some embodiments the present invention provides methods of treating a tumor in a subject. In some embodiments the methods may include a step of administering to the subject a therapeutic composition that comprises: (a) mycophenolic acid an analogue thereof or a derivative thereof; and (b) at least one anti-neoplastic agent. In some embodiments the anti¬ neoplastic agent may include at least one of 5-fluouracil (5-FU) paclitaxel oxaliplatin doxorubicin etoposide irinotecan bleomycin imiquimod ...

The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4- chlorophenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and a topoisomerase inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the topoisomerase inhib...